Skip to main content
Figure 4 | Molecular Cancer

Figure 4

From: Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities

Figure 4

The Bax:Bcl-2 ratio measured by Western blot analysis. Four treatment groups: control (CTL); 40 μM dexamethasone (DXM) for 8 h; 100 μM temozolomide (TMZ) for 6 h; pretreatment with 40 μM DXM for 2 h followed by 100 μM TMZ for 6 h. (A) A representative gel picture showing level of expression of Bax. (B) A representative gel picture showing level of expression of Bcl-2. (C) A representative gel picture showing level of expression of β-actin. (D) Densitometric analysis showing the Bax:Bcl-2 ratio in all treatment groups. Significant difference between CTL and TMZ treated cells was indicated by * (P ≤ 0.05) and significant difference between TMZ treated cells and DXM plus TMZ treated cells was indicated by # (P ≤ 0.05).

Back to article page

Molecular Cancer

ISSN: 1476-4598